Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 2153629, 11 pages
https://doi.org/10.1155/2017/2153629
Research Article

Intravenous Administration of Adipose-Derived Stem Cell Protein Extracts Improves Neurological Deficits in a Rat Model of Stroke

1Department of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China
2Neuroinflammation Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4
3Department of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China
4Department of Neurosurgery, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, China

Correspondence should be addressed to Hongwei Xu; moc.liamtoh@65iewgnoh and Lixian Li; moc.anis@ydhzxll

Received 5 September 2016; Revised 21 November 2016; Accepted 27 November 2016; Published 7 February 2017

Academic Editor: Marc L. Turner

Copyright © 2017 Kai Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Figure 1. Measurement of Neurological deficits using Roger's scaling system. (A) tMCAO was induced using SD rat. Protein extract from ADSCs (ADSC-E) was injected either through IV, IC or IP after the operation. The impact of different delivery routes on the therapeutic effect of ADSC-E during stroke were measured by Roger's scaling system (n=8/group). (B) tMCAO was induced using SD rat. Either ADSC or ADSC-E was injected through IV. The therapeutic characteristics between ADSC and ADSC-E on behavior change were measured by Roger's scaling system (n=8/group).Supplementary Figure 2. The impact of different components of ADSC during stroke. tMCAO was induced using SD rat. Different components (ADSC-E, Heated-ADSC-E, RNA and DNA) of ADSC were injected through IV. (A, B). Functional outcome was measured by mNSS Scaling system (n=4/group) (A) and Roger's Scaling system (n=4/group) (B). (C, D). Lesion size was measured using TTC staining at day 1 (n=4/group).

  1. Supplementary Material